Live Analyst Rating Changes 22494 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Eva Fortea Verdejo
WF

Eva Fortea Verdejo

Wells Fargo
Wall Street Analyst
★★★★★
#183
on 13Foresight · ranked by our own returns
78%
Success Rate
+13.9%
Average Return
18 of 23 calls profitable · +9.3% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 78% of Eva Fortea Verdejo's ratings turned a profit when each position was held for 1 year — averaging +13.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

56 Buy 18 Hold 0 Sell
Eva's Stock Coverage 14 ratings · 2026-08-11
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
ZYME
Zymeworks
 Aug 07, 2026 BUY Strong Buy
+38.6% avg upside
25 analysts
$40.00
65.62% Upside
 · ·
RVMD
Revolution Medicines
 Aug 06, 2026 BUY Strong Buy
-19.0% avg upside
32 analysts
$240.00
15.97% Upside
 +3.1% ·
RCUS
Arcus Biosciences
 Aug 06, 2026 HOLD Strong Buy
+24.1% avg upside
20 analysts
$26.00
9.56% Downside
 +0.3% ·
IDYA
IDEAYA Biosciences
 Aug 05, 2026 BUY Strong Buy
+32.1% avg upside
29 analysts
$48.00
30.64% Upside
 +0.5% ·
KNSA
Kiniksa Pharmaceuticals
 Jul 29, 2026 BUY Strong Buy
+0.7% avg upside
11 analysts
$87.00
13.76% Upside
 -3.8% ·
CELC
Celcuity
 Jul 14, 2026 BUY Strong Buy
+36.6% avg upside
16 analysts
$166.00
82.86% Upside
 -19.2% ·
EXEL
Exelixis
 Jul 13, 2026 HOLD Buy
-17.9% avg upside
34 analysts
$49.00
7.55% Downside
 -7.2% ·
GMAB
Genmab
 Jun 29, 2026 BUY Buy
+16.4% avg upside
27 analysts
$40.00
29.58% Upside
 +20.1% ·
BCAX
Bicara Therapeutics Inc.
 Jun 01, 2026 HOLD Strong Buy
+12.0% avg upside
14 analysts
$16.00
42.29% Downside
 +36.1% ·
RLAY
Relay Therapeutics
 May 19, 2026 BUY Strong Buy
+9.0% avg upside
21 analysts
$21.00
5.38% Upside
 +63.8% ·
ZNTL
Zentalis Pharmaceuticals
 May 13, 2026 HOLD Buy
+237.2% avg upside
18 analysts
$5.00
20.57% Upside
 -3.0% ·
IMCR
Immunocore Holdings
 Apr 14, 2026 BUY Strong Buy
+89.6% avg upside
22 analysts
$60.00
76.56% Upside
 +7.2% ·
STRO
Sutro Biopharma
 Mar 24, 2026 BUY Strong Buy
+55.5% avg upside
21 analysts
$27.00
5.81% Upside
 +7.7% ·
XNCR
Xencor
 Oct 23, 2025 BUY Strong Buy
+62.3% avg upside
27 analysts
$27.00
25.14% Upside
 +68.6% ·
🔒 9 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Eva Fortea Verdejo — Frequently Asked Questions
How accurate are Eva Fortea Verdejo's stock ratings?
Based on the calls 13Foresight could measure, about 74% of Eva's ratings were profitable over a one-year hold, with an average return of +14.0% per rating, or +9.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Eva ranked on 13Foresight?
Eva Fortea Verdejo is currently ranked #183 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Eva cover?
Eva most recently has ratings on ZYME, RVMD, RCUS, IDYA, KNSA, CELC, EXEL, GMAB, BCAX, RLAY, ZNTL, IMCR and 2 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.